文献速递头颈与中枢神经肿瘤

WT1肽疫苗乳剂治疗儿童复发/难治性DIPG、胶质母细胞瘤或间变性星形细胞瘤的1/2期研究

Phase 1/2 study of a WT1 peptide-dosing emulsion in pediatric patients with recurrent/refractory diffuse intrinsic pontine glioma, glioblastoma, or anaplastic astrocytoma.
PubMed 文献 · Eur J Cancer · 2026-05-19

这项首次在儿童中开展的1/2期研究评估了WT1肽疫苗在复发/难治性DIPG、胶质母细胞瘤或间变性星形细胞瘤患儿中的安全性和疗效。全组18例患者中,注射部位反应最常见(77.8%),未发生剂量限制性毒性,2期剂量定为3.5 mg。DIPG患者9个月总生存率为27.3%,因90%CI下限未超过预设阈值20%,疫苗在统计学上无效;但WT1特异性免疫应答者的中位OS显著长于无应答者(9.9个月 vs 4.9个月,p=0.024)。

要点

  • 疫苗耐受性良好,最常见不良事件为注射部位反应(77.8%),未达剂量限制性毒性。
  • DIPG患者9个月OS率为27.3%,未超过预设疗效阈值,主要终点未达统计学显著。
  • WT1特异性免疫应答者中位OS显著优于无应答者(9.9个月 vs 4.9个月,p=0.024)。

核心结论

  • 疫苗在统计学上未显示疗效,但耐受性良好,并似乎诱导了WT1特异性免疫应答。
  • 在DIPG患者中,WT1特异性免疫应答者提示生存改善,值得进一步开发。

研究设计与样本

  • 首次在儿童中开展的1/2期研究,纳入<20岁的复发/难治性DIPG、胶质母细胞瘤或间变性星形细胞瘤患者。
  • 全组共18例,中位年龄8.9岁;DIPG 11例,胶质母细胞瘤5例,间变性星形细胞瘤2例。
  • 1期4例未出现剂量限制性毒性,确定3.5 mg用于2期14例。
  • 主要终点为9个月总生存率。

主要发现

  • 注射部位反应最常见,共14例(77.8%)。
  • 全组患者9个月OS率为44.4%(90%CI 24.4-65.9)。
  • DIPG患者9个月OS率为27.3%(90%CI 7.9-56.4),中位OS为5.4个月。
  • WT1特异性免疫应答者中位OS为9.9个月(6.0-33.4),显著长于无应答者的4.9个月(2.2-16.5),p=0.024。

关键数值与推荐

  • DIPG患者主要疗效终点未达统计学显著,因90%CI下限未超过预设阈值20%。

临床怎么用

  • 该疫苗在儿童复发/难治性高级别胶质瘤中耐受性良好,但当前方案未达主要疗效终点。
  • WT1特异性免疫应答与更长的总生存相关,支持进一步开发该疫苗。

局限性

  • 样本量小(N=18),为单臂研究,未设对照。
  • 主要疗效终点在DIPG患者中未达预设阈值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The prognosis of pediatric patients with diffuse intrinsic pontine glioma (DIPG), glioblastoma, or anaplastic astrocytomas (AAs) is dismal. This first-in-child phase 1/2 study examined the safety and efficacy of a Wilms' tumor gene 1 (WT1) peptide vaccine, along with the associations of delayed-type hypersensitivity (DTH) and cytotoxic T lymphocyte (CTL) frequency/count with clinical outcomes. METHODS: Patients (<20 years) were intradermally injected with the vaccine. RESULTS: Among all patients (N = 18; median age: 8.9 years), 11, 5, and 2 had DIPG, glioblastoma, and AAs, respectively. In Phase 1 (n = 4), 3.5 mg was determined for use in Phase 2 (n = 14) because no dose-limiting toxicities occurred. In Phases 1 and 2, injection site reactions (n = 14, 77.8%) were the most common adverse events. All and DIPG patients showed the 9-month overall survival (OS) rates-the primary endpoint-of 44.4% (90% confidence interval (CI) [24.4-65.9]) and 27.3% [7.9-56.4], respectively. The vaccine was not effective statistically because the lower limit of the 90% CI for the primary efficacy endpoint in DIPG patients did not exceed its prespecified threshold-20%. Median OS was 5.4 months for DIPG. Among all patients, median OS was significantly longer (p = 0.024) for WT1-specific immune responders (9.9 months [6.0-33.4]) presenting increased CTL frequency/count and/or being positive for DTH than for nonresponders (4.9 months [2.2-16.5]). CONCLUSIONS: The vaccine was not effective statistically but was well tolerated and appeared to have induced WT1-specific immune responses, suggesting improved survival in WT1-specific immune responders among DIPG patients and warranting its further development. CLINICALTRIALS: gov Identifier: NCT02750891.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Hashii Y, Fujisaki H, Terashima K, et al. Phase 1/2 study of a WT1 peptide-dosing emulsion in pediatric patients with recurrent/refractory diffuse intrinsic pontine glioma, glioblastoma, or anaplastic astrocytoma. Eur J Cancer. 2026. PMID: 42176363. doi:10.1016/j.ejca.2026.116808

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。